Medical Market Report

Global Anti-Obesity Prescription Drugs Market By Type (Proton Pump Inhibitor, H2 Antagonist, And Acid Neutralizers), By Application (Tablet, Liquid, And Powder), By Region And Key Companies - Industry Segment Outlook, Market Assessment, Competition Scenario, Trends And Forecast 2020-2029

  • 133907
  • 12-Dec
  • PDF/PPT/Word
  • ★ ★ ★ ★ ★
    ★ ★ ★ ★ ★
  • Report Details

    The report on Anti-Obesity Prescription Drugs Market offers in-depth analysis on market trends, drivers, restraints, opportunities etc. Along with qualitative information, this report include the quantitative analysis of various segments in terms of market share, growth, opportunity analysis, market value, etc. for the forecast years. The global anti-obesity prescription drugs market is segmented on the basis of Type, Application, and geography.
    The global Anti-Obesity Prescription Drugs market was valued at US$ XX.X Mn in 2018 and is projected to increase significantly at a CAGR of x.x% from 2019 to 2028.

    Anti-Obesity Prescription Drugs Market Scope:

    By type, the market is segmented into Orlistat, Phentermine and Topiramate, Bupropion and Naltrexone, Lorcaserin, and Liraglutide. By Application, the market is divided into Pediatric, and Adult.
    Based on geography, market is analyzed across North America, Europe, Asia-Pacific, Latin America, and Middle East and Africa. Major players profiled in the report include F Hoffmann La Roche Ltd, Orexigen Therapeutics, Inc, Novo Nordisk A/s, Arena Pharmaceuticals, Inc, Glaxosmithkline, Vivus, Inc, Boehringer Ingelheim, and Alizyme

    .

    Key Market Segments

    Type

    Orlistat
    Phentermine and Topiramate
    Bupropion and Naltrexone
    Lorcaserin
    Liraglutide

    Application

    Pediatric
    Adult

    Key Market Players included in the report:

    F Hoffmann La Roche Ltd
    Orexigen Therapeutics, Inc
    Novo Nordisk A/s
    Arena Pharmaceuticals, Inc
    Glaxosmithkline
    Vivus, Inc
    Boehringer Ingelheim
    Alizyme

    Reasons to Get this Report:

    In an insight outlook, this research report has dedicated to several quantities of analysis industry research (global industry trends) and Anti-Obesity Prescription Drugs Market share analysis of high players, along with company profiles, and which collectively include about the fundamental opinions regarding the market landscape; emerging and high-growth sections of Anti-Obesity Prescription Drugs Market; high-growth regions; and market drivers, restraints, and also market chances.
    The analysis covers Anti-Obesity Prescription Drugs Market and its advancements across different industry verticals as well as regions. It targets estimating the current market size and growth potential of the global Anti-Obesity Prescription Drugs Market across sections such as also Application and representatives.
    Additionally, the analysis also has a comprehensive review of the crucial players on the Anti-Obesity Prescription Drugs Market together side their company profiles, SWOT analysis, latest advancements, and business plans.

    The analysis objectives of the report are:

    To equitably share in-depth info regarding the crucial elements impacting the increase of industry (growth capacity, chances, drivers, and industry-specific challenges and risks).
    To know the Anti-Obesity Prescription Drugs Market by pinpointing its many subsegments.
    To profile the important players and analyze their growth plans.
    To endeavor the amount and value of Anti-Obesity Prescription Drugs sub-markets, depending on key regions (various vital states).
    To analyze Anti-Obesity Prescription Drugs Market concerning growth trends, prospects, and also their participation in the entire sector.
    To examine and study the Anti-Obesity Prescription Drugs Market size (volume & value) from the company, essential regions/countries, products, and Application, background information from 2012 to 2018, and also prediction to 2028.
    Primary worldwide Anti-Obesity Prescription Drugs Market manufacturing companies, to specify, clarify and analyze the product sales amount, value and market share, market rivalry landscape, SWOT analysis and development plans next coming years.
    To examine competitive progress such as expansions, arrangements, new product launches, and acquisitions on the market.

  • Table Of Content 
    1. Anti-Obesity Prescription Drugs Market Introduction
    

    1.1. Definition
    
1.2. Taxonomy
    
1.3. Research Scope2. Executive Summary
    

    2.1. Key Findings by Major Segments
    
2.2. Top strategies by Major Players3. Global Anti-Obesity Prescription Drugs Market Overview
    

    3.1. Anti-Obesity Prescription Drugs Market Dynamics
    

    3.1.1. Drivers
    
3.1.2. Opportunities
    
3.1.3. Restraints
    
3.1.4. Challenges3.2. PESTLE Analysis
    
3.3. Opportunity Map Analysis
    
3.4. PORTER’S Five Forces Analysis
    
3.5. Market Competition Scenario Analysis
    
3.6. Product Life Cycle Analysis
    
3.7. Opportunity Orbits
    
3.8. Manufacturer Intensity Map4. Global Anti-Obesity Prescription Drugs Market Value ((US$ Mn)), Share (%), and Growth Rate (%) Comparison by Type, 2012-2028
    

    4.1. Global Anti-Obesity Prescription Drugs Market Analysis by Type: Introduction
    
4.2. Market Size and Forecast by Region
    
4.3. Orlistat
    
4.4. Phentermine and Topiramate
    
4.5. Bupropion and Naltrexone
    
4.6. Lorcaserin
    
4.7. Liraglutide5. Global Anti-Obesity Prescription Drugs Market Value ((US$ Mn)), Share (%), and Growth Rate (%) Comparison by Application, 2012-2028
    

    5.1. Global Anti-Obesity Prescription Drugs Market Analysis by Application: Introduction
    
5.2. Market Size and Forecast by Region
    
5.3. Pediatric
    
5.4. Adult6. Global Anti-Obesity Prescription Drugs Market Value ((US$ Mn)), Share (%), and Growth Rate (%) Comparison by Region, 2012-2028
    

    6.1. North America
    

    6.1.1. North America Anti-Obesity Prescription Drugs Market: Regional Trend Analysis
    

    6.1.1.1. US
    
6.1.1.2. Canada
    
6.1.1.3. Mexico
    

    6.2.1. Europe
    

    6.2.1. Europe Anti-Obesity Prescription Drugs Market: Regional Trend Analysis
    

    6.2.1.1. Germany
    
6.2.1.2. France
    
6.2.1.3. UK
    
6.2.1.4. Russia
    
6.2.1.5. Italy
    
6.2.1.6. Spain
    
6.2.1.7. Rest of Europe
    

    6.3. Asia-Pacific
    

    6.3.1. Asia-Pacific Anti-Obesity Prescription Drugs Market: Regional Trend Analysis
    

    6.3.1.1. China
    
6.3.1.2. Japan
    
6.3.1.3. Korea
    
6.3.1.4. India
    
6.3.1.5. Rest of Asia
    

    6.4. Latin America
    

    6.4.1. Latin America Anti-Obesity Prescription Drugs Market: Regional Trend Analysis
    

    6.4.1.1. Brazil
    
6.4.1.2. Argentina
    
6.4.1.3. Rest of Latin America
    

    6.5. Middle East and Africa
    

    6.5.1. Middle East and Africa Anti-Obesity Prescription Drugs Market: Regional Trend Analysis
    

    6.5.1.1. GCC
    
6.5.1.2. South Africa
    
6.5.1.3. Israel
    
6.5.1.4. Rest of MEA
    
7. Global Anti-Obesity Prescription Drugs Market Competitive Landscape, Market Share Analysis, and Company Profiles
    

    7.1. Market Share Analysis
    
7.2. Company Profiles
    
7.3. F Hoffmann La Roche Ltd
    

    7.3.1. Company Overview
    
7.3.2. Financial Highlights
    
7.3.3. Product Portfolio
    
7.3.4. SWOT Analysis
    
7.3.5. Key Strategies and Developments7.4. Orexigen Therapeutics, Inc
    

    7.4.1. Company Overview
    
7.4.2. Financial Highlights
    
7.4.3. Product Portfolio
    
7.4.4. SWOT Analysis
    
7.4.5. Key Strategies and Developments7.5. Novo Nordisk A/s
    

    7.5.1. Company Overview
    
7.5.2. Financial Highlights
    
7.5.3. Product Portfolio
    
7.5.4. SWOT Analysis
    
7.5.5. Key Strategies and Developments7.6. Arena Pharmaceuticals, Inc
    

    7.6.1. Company Overview
    
7.6.2. Financial Highlights
    
7.6.3. Product Portfolio
    
7.6.4. SWOT Analysis
    
7.6.5. Key Strategies and Developments7.7. Glaxosmithkline
    

    7.7.1. Company Overview
    
7.7.2. Financial Highlights
    
7.7.3. Product Portfolio
    
7.7.4. SWOT Analysis
    
7.7.5. Key Strategies and Developments7.8. Vivus, Inc
    

    7.8.1. Company Overview
    
7.8.2. Financial Highlights
    
7.8.3. Product Portfolio
    
7.8.4. SWOT Analysis
    
7.8.5. Key Strategies and Developments7.9. Boehringer Ingelheim
    

    7.9.1. Company Overview
    
7.9.2. Financial Highlights
    
7.9.3. Product Portfolio
    
7.9.4. SWOT Analysis
    
7.9.5. Key Strategies and Developments7.10. Alizyme
    

    7.10.1. Company Overview
    
7.10.2. Financial Highlights
    
7.10.3. Product Portfolio
    
7.10.4. SWOT Analysis
    
7.10.5. Key Strategies and Developments
    

    8. Assumptions and Acronyms
    
9. Research Methodology
    
10. Contact
  • Inquiry Before Buying

    Inquiry Form

  • Request Sample

    Request for Sample

Related Reports

Office Address
Prudour Pvt. Ltd. 420 Lexington Avenue Suite 300 New York City, NY 10170.